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Abstract
Background: While intensity modulated radiotherapy (IMRT) in anal cancer is feasible and improves high-dose
conformality, the current RTOG/AGITG contouring atlas and planning guidelines lack specific instructions on how to
proceed with external genitalia. Meanwhile, the RTOG-Protocol 0529 explicitly recommends genital sparing on the
basis of specific genital dose constraints. Recent pattern-of-relapse studies based on conventional techniques suggest
that marginal miss might be a potential consequence of genital sparing. Our goal is to outline the potential scope and
increase the awareness for this clinical issue.
Methods: We present and discuss four patients with perigenital spread in anal cancer in both early and advanced
stages (three at time of first diagnosis and one in form of relapse). Genital/perigenital spread was observed once as
direct genital infiltration and thrice in form of perigenital lymphatic spread.
Results: We review the available data regarding the potential consequences of genital sparing in anal cancer.
Pattern-of-relapse studies in anal cancer after conventional radiotherapy and the current use of IMRT in anal
cancer are equivocal but suggest that genital sparing may occasionally result in marginal miss. An obvious
hypothesis suggested by our report is that perigenital lymphovascular invasion might be associated with
manifest inguinal N+ disease.
Conclusions: Local failure has low salvage rates in recent anal cancer treatment series. Perigenital spread may
pose a risk of marginal misses in IMRT in anal cancer. To prevent marginal misses, meticulous pattern-of-relapse
analyses of controlled IMRT-series are warranted. Until their publication, genital sparing should be applied with
caution, PET/CT should be used when possible and meeting genital dose constraints should not be prioritized
over CTV coverage, especially (but not only) in stage T3/4 and N+ disease.
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Background
Organ preserving combined modality treatment has proven
to be as effective as radical surgery and has been introduced
as standard therapy for anal cancer worldwide [1–4]. Anal
cancer is currently a highly curable neoplasm with radio-
therapy and concurrent chemotherapy with 5-fluorouracil
(5FU) and mitomycin C (MMC). Disease free survival lies
between 70 and 90 %, depending on tumor size [5–8]. In
modern series, salvage rates for local relapse are lower than
in historic series, which probably is a consequence of better
overall results based on changing biology with increasing
infections with human papillomavirus (HPV) and improved
treatment quality, resulting in less but more therapy-
resistant relapses. Therefore, local relapse dramatically
influences overall survival [9].
When compared to standard anterior-posterior/posterior-
anterior (ap-pa) or 3D-conformal radiotherapy (3D-CRT,
typically with a 3-field or 4-field box technique), intensity
modulated radiotherapy (IMRT) provides similar coverage
of the planning target volume (PTV) while better sparing or-
gans at risk (OAR), reducing the dose to critical structures
[10–19] and according to an initial report of the RTOG
(Radiation Therapy Oncology Group) phase II trial 0529
(though not meeting the primary endpoint) reducing
acute toxicity as a consequence [20]. As IMRT can pro-
duce a highly conformal dose distribution with steep
dose gradients outside the target volume there is the
need for meticulously defining PTV and OAR. RTOG-
0529 also demonstrated the complexity of the whole
treatment planning chain with 81 % of plans that had
to be modified after initial review [20]. Marginal misses
as a consequence of improved dose conformality have
already been observed in other tumor entities such as
head and neck cancer where IMRT is now the gold
standard [21, 22], and slightly inferior tumor control
rates with IMRT in some though not all randomized
trials might be a result of a change in irradiated vol-
umes [23–25].
The Australasian Gastrointestinal Trials Group (AGITG)
and the RTOG have recently established contouring-
guidelines for IMRT in anal cancer [26, 27]. The protocol
of RTOG-0529 lists several dose constraints for critical
normal structures including the external genitalia and
requests that in every patient an effort should be made
to achieve them [20].
Anal cancer invading genitalia or spreading into
lymphatic structures close to external genitalia has been
observed several times at our department over the last
18 months. All patients had extensive clinical and imaging
workup including FDG-PET/CT (positron emission
tomography/computed tomography) and MRI (magnetic
resonance imaging), for the first time providing the oppor-
tunity to obtain detailed objective visualization of genital/
perigenital spread [28]. As local relapse dramatically
influences overall survival, as recently shown by Mai
et al. [9], avoiding marginal misses becomes a crucial
factor in treatment planning in IMRT of anal cancer.
To outline the potential scope and increase the aware-
ness for this clinical issue, in this report we present
one case of anal carcinoma with a perivulvar/vulvar re-
lapse after IMRT and three cases of anal cancer with
(peri)genital infiltration at the time of first diagnosis before
IMRT treatment and discuss them in the context of re-
cently published relevant data. All patients have consented
with their regular informed consent to anonymous scien-
tific analysis of their data.
Case reports
Direct genital infiltration
Case 1
A 50-year-old male patient presented with T2N0M0 anal
margin squamous cell carcinoma (SCC) in 04/2013, with
the tumor reaching the posterior scrotal skin (Fig. 1, Ia-c).
He received concurrent radiochemotherapy with 2 cycles
of 5FU/MMC and IMRT with 36 Gy to the pelvis and
inguinal lymph nodes, followed by 45 Gy to the primary
tumor and pelvis (without inguinal lymph nodes) and a
perineal electron boost to the macroscopic tumor up to
50.4 Gy. The area of the scrotal skin that was considered
infiltrated was included in the boost field. Follow-up has
been without signs of relapse.
Perigenital involvement related to lymphatic spread
Case 2
A 52-year-old female patient presented with T3N3M0
anal canal SCC in 03/2012. She received IMRT with 45 Gy
to the pelvis (including inguinal and paraaortic lymph
nodes) and a boost up to 54 Gy to the primary tumor and
PET-positive lymph nodes. Two concurrent and two se-
quential cycles of 5FU/MMC chemotherapy were ad-
ministered. The second follow-up at four months with
FDG-PET/CT showed an elevated SUV in most of the
initially affected lymph nodes and a biopsy of the anal
canal revealed persisting carcinoma. Salvage surgery was
performed (abdominoperineal resection and systematic
inguinal lymphadenectomy). Due to a postoperatively
persisting lymphatic fistula in the left inguinal region, a
course of obliterating radiotherapy was planned. The
planning CT unexpectedly showed a small subcutaneous
tumor in the right vulvar/perivulvar region. A control CT
4 weeks after radiotherapy showed a significant increase
in size, suggesting locoregional relapse (Fig. 1, IIa-h). As
surgery was not considered an option due to elevated risk
of wound healing impairment, she received low-dose-rate
brachytherapy (10 Gy). Local control and improvement
of local wound situation were achieved for several weeks.
As she developed multilocular failure some weeks later,
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Fig. 1 Direct genital infiltration and perigenital involvement and/or perivulvar relapse in anal carcinoma: PET/CT images and clinical manifestation.
Legend: (I) Direct genital infiltration in N0/N3 anal cancer at time of first diagnosis (case 1) with PET/CT images in transversal and sagittal planes (Ia, b)
and clinical photo (Ic); (II) Vulvar/perivulvar relapse 9 months after concurrent IMRT and chemotherapy of an inguinally N+ anal cancer (case 2) with the
CT-sequence of the development of the relapse from time of first diagnosis until 9 months after radiochemotherapy (IIa), pretherapeutic PET/CT images
in transversal and coronal planes (IIb, c), IMRT plans in transversal and coronal planes with isodose details (IId, e, f), CT image of the relapse in coronal
plane and clinical photo at 9 months after therapy (IIg, h); (III) and (IV) Perigenital involvement related to lymphatic spread in inguinally N+ anal cancer at
time of first diagnosis (case 3 and case 4) with PET/CT images in transversal and coronal planes (IIIa, b and IVa, b, c) and clinical photo (IIIc and IVd)
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palliative chemotherapy was initiated. A few months later,
she died in palliative care.
Case 3
A 55-year-old female patient presented with a T2N2M0
anal canal SCC in 09/2012. A PET/CT showed an affected
inguinal lymph node and perigenital lymphatic infiltration
on the left side (Fig. 1, IIIa, b). Fig. 2 shows MRI images of
the perigenital infiltration (Fig. 2, left side). Clinically, the
patient also had tumor infiltration of the left mons pubis
(Fig. 1, IIIc). IMRT was applied with 45 Gy to the pelvis
and both inguinal lymphatic regions, with a boost up to
54 Gy to the PET-positive primary tumor and left inguinal
lymph nodes. Two concurrent and two sequential cycles
of chemotherapy with 5FU/MMC were administered.
Follow-up has been without signs of relapse.
Case 4
In 02/2013, a 69-year-old female patient presented with
T4N3M0 anal canal SCC with infiltration of the vagina
and PET-positive inguinal lymph nodes with left perivul-
var infiltration (Fig. 1, IVa-d). Fig. 2 shows MRI images
of the perigenital infiltration (Fig. 2, right side). IMRT
was applied to the pelvis including the inguinal lymph
nodes on both sides up to 45 Gy and a boost to the pri-
mary tumor including the vulva and all PET-positive
Fig. 2 Perigenital involvement in anal carcinoma: MR images Legend: Representative MR images of case 3 (left) and case 4 (right) in transversal
and sagittal planes showing perigenital involvement in anal carcinoma in a T1 weighted sequence after administration of contrast agent
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lymph nodes up to 54 Gy. As one concurrent 5FU/
MMC chemotherapy cycle lead to febrile leucopenia,
urosepsis and cardiac complications, chemotherapy was
concluded at 3 cycles of cisplatin (week 7, 14, 19). After
3 months the patient presented with progressive PET-
positive paraaortic and presacral lymph nodes and at
4 months a residual tumor in the anal canal was diag-
nosed. Additionally, clinical examination showed new
small vulvar nodes, which were biopsied and classified
as vulvar intraepithelial neoplasia (VIN). The patient re-
ceived salvage surgery (abdominoperineal resection and
removal of the large left labium). Upon follow-up at six
weeks after salvage surgery, the patient presented with
progressive inguinal lymph nodes. A solitary pulmonary
metastasis was resected in 11/2013. Due to further pro-
gressive disease in 01/2014, she received palliative
chemotherapy and died several months later.
Discussion
Evidently, the four cases reported here cannot be repre-
sentative for the whole group of patients with genital in-
volvement in anal cancer, but are certainly hypothesis-
generating. They clearly demonstrate that involvement
of external genitalia does in fact occur clinically, may be
subtle, is not necessarily related to a large primary tumor
and has therefore to be considered when defining target
volumes.
Anal cancer spreads locoregionally both contiguously
and along lymphatic vessels. Inguinal and pelvic nodes
are at risk, especially for large primary tumors [29–32].
External genitalia can be involved for three potential
reasons: synchronous genital primaries because of vir-
ally induced field cancerogenesis, direct invasion of the
primary tumor and finally perigenital lymphatic spread
that invades the genitals. In a study of Fenger et al., half
of the female patients with anal intraepithelial neoplasia
(AIN) had accompanying or previous neoplasia of the
vulva or perineum [33], likely manifesting field canceri-
zation as a consequence of HPV infection. Case 4 in
our report may represent such a situation with anal
cancer instead of AIN, as the HPV analysis (of both pri-
mary anal tumor and VIN) showed a HPV+ and p16+
tumor. However, as HPV is positive in about 90 % of
the patients with anal cancer [34–36], a positive result
for HPV in anal cancer doesn’t prove a direct link be-
tween the anal cancer and the genital disease. The inci-
dence of synchronous HPV related tumors is not yet
known and the other two reasons for genital invasion
(direct infiltration and perigenital lymphatic spread) are
likely more relevant for target delineation and shall
therefore be discussed below more in detail.
In regard to diagnostic imaging for treatment plan-
ning in anal cancer, recommendations slightly differ in
various international guidelines. The NCCN (National
Comprehensive Cancer Network) guidelines recommend
CT or MRI of the pelvis for evaluation of pelvic lymph
nodes [26]. A FDG-PET/CT can assess N+ disease and
also provides detailed visualization of genital/perigenital
spread [32, 37]. The NCCN guidelines, updated in 2012
after a NCCN Anal Carcinoma Panel meeting, state
after thorough interdisciplinary discussion that “PET/CT
should be considered for treatment planning” [38, 39].
Mai et al. showed the possibility of dose reduction in in-
guinal lymph node regions on the basis of FDG-PET/CT
[28]. In our opinion, performing a PET/CT for treatment
planning therefore should be considered, when available.
As for patient setup, radiation treatment in anal cancer
can be performed in prone or supine position with both
advantages and disadvantages in each position [32]. Re-
garding genital sparing, a “frog legged” supine position
allows avoiding unnecessary radiation dermatitis by
separation of the medial thighs. For female patients,
the use of a genital dilator may further improve vaginal
sparing [40].
In the last decade, IMRT has become a widely used
radiotherapy technique for various tumor entities such
as head and neck, prostate or breast cancer [41]. The
steep dose gradients created by IMRT bear the potential
to increase the rate of marginal misses, and both anec-
dotal evidence [21, 22] and results from randomized trials
[23, 24] have raised the awareness towards this issue. By
now, IMRT is increasingly used for anal cancer within the
framework of radiochemotherapy, both as step-and-shoot/
dynamic IMRT and as volumetric modulated arc therapy
(VMAT) [42]. Performing highly conformal radiotherapy
with IMRT in anal cancer requires detailed knowledge of
target structures for delineating the complex elective
nodal regions without omitting any important tumor
volume. There have recently been efforts within the
RTOG and the AGITG to address the question as how
exactly to contour the region of the primary tumor and
elective target volumes while sparing femoral head and
neck, bladder, bowel and external genitalia [26, 27]. In
a contouring atlas, detailed recommendations and guide-
lines for delineating the PTV are given. Regarding OAR
however, statements have so far remained vague. Up to
now, there exist no specific data on how to best spare
sensitive structures without compromising the target
coverage. Only the protocol of RTOG-0529 lists several
dose constraints for critical normal structures including
the external genitalia and requests that in every patient
an effort should be made to achieve them, without giv-
ing contouring recommendations: no more than 50 %
of the external genitalia should receive a dose above
20 Gy, no more than 35 % a dose above 30 Gy, and no
more than 5 % a dose above 40 Gy [20].
Although the primary endpoint of reducing grade 2
toxicity was not met, the initial data published for this
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RTOG-0529 multicenter trial suggest reduced grade 3
toxicity (likely even more important than the primary
endpoint) with IMRT [20] when compared to the sem-
inal RTOG-9811 trial where the conventional radiation
treatment still was ap-pa or a 3D-conformal multifield
technique [6, 43]. There have been various other clinical
studies that indicate similar or reduced acute toxicities for
IMRT when compared to 3D-CRT [11–15, 17, 18, 20, 44].
Finally, in a dosimetric study, Chen et al. explicitly showed
that external genitalia can be spared by IMRT [10].
To better understand to what extent genitals can actu-
ally be spared from treatment, pattern-of-relapse analyses
have to be performed. Two recent studies have reported
such patterns-of-relapse in anal cancer after conventional,
simulator based therapy. Relapses have mostly occurred
locally in the area of the primary tumor or regionally in
initially affected lymph node areas [45, 46] and can there-
fore most likely be considered in-field, which is to be ex-
pected given the large volumes treated with conventional
techniques. Das et al. report that 75 % of relapses involved
the anus or rectum, with or without involvement of other
structures, without elaborating, though, on how many re-
lapses might have been due to marginal misses. Their
number is likely small, however, because the majority of
dose was applied ap-pa and only part of the treatment was
given with a 3-field technique with some anterior genital
sparing [45]. Wright et al., on the other hand, apparently
performed explicit genital blocking for a large part of the
treatment. Locoregional failure overall was significantly
associated with T-stage but not N-stage. In detail, patients
with external perianal failure had stages from T1N0 up to
T3N0 and the two patients with vulvar and scrotal relapse
had T2N2 and T2N3 stage, respectively. Both patients
with genital relapses had also both inguinal relapse and fi-
nally metastatic disease. Though an ultimately precise
analysis of in-field relapse vs. marginal miss was not pos-
sible in their series either due to methodical limits (no
rigorous image review, physician assessment only), they
explicitly suggest that “three of five failures appear to be
in-field and two marginal, primarily because of inadequate
coverage anteriorly. Failures occurred up to 3 cm inferior
to the anal verge and anteriorly into the scrotum or vulva.
This highlights the need to respect a minimum of a 2-cm
margin on the tumor and anal margin in the CTV, even if
this makes meeting genital dose constraints difficult” [46].
Regarding IMRT, there is a body of retrospective data
that reports local and regional control after IMRT for anal
cancer, albeit still with relatively short follow-up, with a
varying degree of genital sparing, a varying percentage of
local and regional relapse and no explicit analysis to what
extent genital sparing may have contributed to local and
regional relapse [11–16, 19, 47–49]. A full publication of
the post-IMRT tumor control data from RTOG-0529
cannot be found so far.
In the series presented here, one patient (case 2, ini-
tially T3N3M0) showed a vulvar/perivulvar relapse indi-
cating marginal miss (Fig. 1, IIa, g, h). The relapse
occurred thirteen months after primary diagnosis. The
area of the relapse had been in the margin of the radi-
ation field and had received approximately 41–46 Gy
(Fig. 1, IId, f ). As there had been no sign of vulvar/peri-
vulvar tumor at time of first diagnosis (Fig. 1, IIb, c), nor
at posttreatment up to 5 months, we assume microscopic
perigenital lymphovascular invasion and vulvar relapse
due to insufficient radiation dose. However, as the patient
also had persisting tumor in the anal canal (high dose
region), treatment failure in this case was likely caused
by multiple tumor-biological factors and not only by
marginal miss.
The other three cases report genital/perigenital infiltra-
tion already at time of first diagnosis, before application of
IMRT, therefore treatment volumes could be chosen ap-
propriately. In case 1 (T2N0M0), scrotal infiltration could
not be ruled out clinically and consequently the clinically
infiltrated parts of the scrotum/scrotal skin were included
into the CTV. In case 3 (T2N2M0 with infiltration of the
left inguinal lymph node), clinically there was considerable
infiltration of the left mons pubis, demonstrating a case of
perigenital lymphovascular invasion. The right inguinal re-
gion had shown no sign of affected lymph nodes at the
start of the treatment but the patient was considered to be
at higher risk of having further (microscopic) lymph node
infiltration or inguinal relapse. Therefore, radiation on the
right side purposely was performed not only with 36 Gy
but up to 45 Gy, in order to apply a sufficient radiation
dose to both inguinal regions. Both patients have been in
remission to date, likely as a consequence of the relatively
large treatment volumes and target contouring being
based both on clinical and PET/CT examination, the latter
unfortunately not yet being a standard imaging modality
in anal cancer. Case 4 was an advanced T4N3M0 tumor
with initial involvement of inguinal lymph nodes on both
sides with perivulvar lymphovascular invasion on the left
side. The infiltrated genital area was included into the
PTV. Due to persisting anal tumor and progressive lymph
nodes salvage surgery was performed. She later received
palliative chemotherapy due to multilocular progression
and died a few months later in palliative care.
Case 2 and case 4 therefore show cases with locoregio-
nal failure and subsequent systemic progressive disease.
In the context of systemic progressive disease the issue
of local failure is sometimes of minor prognostic import-
ance, the consequences for the patient (e.g. painful local
complications) may nevertheless be severe. However, it
has also to be kept in mind that, as recently shown by
Mai et al., as well as in other recent publications, local
relapse is not salvaged any more at recently published
rates and thus dramatically influences overall survival
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[9], which is supported by our cases. Possibly, uncon-
trolled local disease increases the risk for systemic
spread.
Conclusions
In conclusion, while IMRT in anal cancer is feasible and
improves high-dose-conformality, our case reports show
that in both early and advanced anal tumors there is a
risk of genital/perigenital spread at time of first diagnosis,
increasing the risk for marginal misses if target volumes
are too small. Genital spread can occur in form of direct
infiltration (which may not only occur in high T-stage) or
perigenital lymphovascular invasion (for which a hypoth-
esis suggested by this report is that it may be associated
with inguinal N+ disease). Until detailed pattern-of-relapse
analyses of controlled IMRT-series such as RTOG-0529
are available, PET/CT and possibly MRI should be consid-
ered as a staging tool, genital sparing should be applied
with caution, and meeting genital dose constraints should
not be prioritized above CTV coverage, especially (but not
only) in stage T3/4 and inguinal N+ disease.
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